A
ACRV
Acrivon Therapeutics, Inc.
1.530
+0.060+4.08%After Hours: 1.491 -0.039 -2.54%17:00 04/08 EDT
OPEN/PREV CLOSE1.560/1.470
TODAY RANGE1.460-1.580
VOL500.38K
MARKET CAP59.28M
52 WEEK RANGE1.050-3.560
AVG VOL (3M)979.47K
% TURNOVER1.29%
TURNOVER--
P/E (TTM)-0.7563
% RANGE8.16%
EPS(TTM)-2.0230
P/E(FORWARD)-0.7251
P/B0.4304
BVPS3.555
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP55.24M
SHARES OUTSTANDING38.74M
NEXT EARNINGS05/12-05/18
FREE FLOAT36.10M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·03/23 08:25
Jefferies Keeps Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)
TipRanks·03/19 11:49
Acrivon Highlights Positive ACR-368 Data and 2025 Results
TipRanks·03/19 11:31
Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study
Reuters·03/19 11:28
Acrivon Therapeutics Q4 net loss narrows as expenses fall
TipRanks·03/19 11:25
Acrivon Therapeutics sees cash runway into 2Q27
Benzinga·03/19 11:23
Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate
Dow Jones·03/19 11:22
*Acrivon Therapeutics 4Q Loss/Shr 49c >ACRV
Dow Jones·03/19 11:22
*Acrivon Therapeutics 4Q Research and Development Expenses $14.7M >ACRV
Reuters·03/17 21:54
Acrivon Therapeutics to present three posters at the AACR Annual Meeting
TipRanks·03/02 12:46
Piper Sandler Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)
Same Industry
Name/Symbol
Change%
Price